高级检索

还少丹联合西药治疗脾肾亏虚型慢性脑缺血眩晕的临床效果

Clinical efficacy of Huanshaodan combined with western medicine in treating chronic cerebral ischemic vertigo of spleen-kidney deficiency

    摘要
  • 摘要:
    目的 观察还少丹联合西药对脾肾亏虚型慢性脑缺血眩晕的临床疗效。
    方法 选取60例脾肾亏虚型慢性脑缺血眩晕患者作为研究对象，将其随机分为对照组和联合组，每组30例。对照组采用倍他司汀和胞磷胆碱治疗，联合组在对照组基础上加用还少丹口服，共治疗4个疗程。观察并比较2组患者治疗效果和治疗前后中医症状积分、血浆同型半胱氨酸(Hcy)水平变化。
    结果 治疗前, 2组患者各项中医症状积分比较，差异有统计学意义(P < 0.05);治疗后, 2组患者各项中医症状积分均低于治疗前，且联合组头晕目眩、倦怠乏力与腰膝酸软、健忘、发作频率积分低于对照组，差异有统计学意义(P < 0.05)。联合组总显效率为60.00%(18/30), 高于对照组的36.67%(11/30), 差异有统计学意义(P < 0.05);联合组总有效率为93.33%(28/30), 高于对照组的83.33%(25/30), 但差异无统计学意义(P>0.05)。治疗前, 2组患者血浆Hcy水平比较，差异无统计学意义(P>0.05);治疗后，联合组、对照组患者血浆Hcy水平依次为(13.14±5.83)、(16.75±7.73)μmol/L, 分别低于治疗前的(20.79±6.52)、(18.56±7.69)μmol/L, 且联合组血浆Hcy水平低于对照组，差异有统计学意义(P < 0.05)。
    结论 在西药治疗基础上联用还少丹，能够更好地减轻脾肾亏虚型慢性脑缺血眩晕患者的临床症状，显著降低血浆Hcy水平，明显改善患者预后。

     

    Abstract:
    Objective To observe the clinical effect of Huanshaodan combined with western medicine in treating chronic cerebral ischemic vertigo of spleen-kidney deficiency type.
    Methods A total of 60 patients with chronic cerebral ischemic vertigo of spleen and kidney deficiency type were selected as study objects, and were randomly divided into control group and combination group, with 30 cases in each group. The patients in the control group were treated with betahistine and citicoline, and those in the combination group orally taken Huanshaodan based on the control group, the treatment was lasted 4 courses of treatment. The therapeutic effect, TCM symptom score and plasma homocysteine (Hcy) level before and after treatment were observed and compared between the two groups.
    Results Before treatment, there were statistically significant differences in scores of TCM symptoms between two groups (P < 0.05); after treatment, scores of TCM symptoms in two groups were lower than before treatment, and scores of dizziness, fatigue, waist and knee weakness, forgetfulness and attack frequency in the combination group were lower than those in the control group (P < 0.05). The total remarked efficiency of the combination group was 60.00% (18/30), which was higher than 36.67% (11/30) of the control group (P < 0.05). The total effective rate of the combined group was 93.33% (28/30), which was higher than 83.33% (25/30) of the control group, but the differences showed not statistically significant (P>0.05). Before treatment, there was no significant difference in plasma Hcy level between two groups (P>0.05). After treatment, plasma Hcy levels in combination group and control group were (13.14±5.83) and (16.75±7.73) μmol/L, which were lower than (20.79±6.52) and (18.56±7.69) μmol/L, respectively before treatment, and the plasma Hcy level in the combination group was lower than that in control group (P < 0.05).
    Conclusion Huanshaodan treatment on the basis of western medicine can better relieve the clinical symptoms of chronic cerebral ischemia vertigo patients with spleen and kidney deficiency, significantly reduce the level of plasma Hcy, and significantly improve the prognosis of patients.

     

    • HTML全文
    • 参考文献(11)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回